Abstract

MYOINOSITOL: A REVIEW OF ITS USE IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME

Chinthana Govindarajan, Revathi Pitchaipillai*, Bhuvaneswari Shanmugasundaram, Sudhananthini Thangam, Jegan Arokiasamy and Manickavasagam Subramania Pillai

ABSTRACT

Polycystic ovarian syndrome (PCOS) or stein - leventhal syndrome is one of the most common endocrine disorders affecting women of reproductive age. The diagnostic criteria of PCOS are Oligo ovulation and/or anovulation, excess androgen activity, polycystic ovaries on ultra sonogram. The estimated prevalence is 36% of women in India are suffering from PCOS and the Global prevalence is 2.2% to 26%. Recently, Myoinositol (MI) - a novel insulin sensitizer has been marketed for PCOS with infertility. Treatment with MI improves the ovarian function, oocyte quality, metabolic and hormonal parameters in PCOS. MI promotes weight loss in PCOS. It has been shown to reduce the systolic and diastolic blood pressure. MI is safe and effective drug and as such there are no side effects and drug interaction at clinically used doses.

Keywords: Polycystic ovarian syndrome, Myoinositol, Ovulation and Oocyte quality, Metabolic dysfunction.